Kai Lipinski joined Vibalogics in 2010 initially as Head of Cell Culture and Virus Production. Kai was named Head of Process Development in 2013, then promoted to Chief Scientific Officer (CSO) in 2020.
Kai has a wealth of experience in viral vector manufacturing from a variety of roles before he joined Vibalogics. He served as Principal Scientist at Cobra Biologics, focusing on upstream process development for virus and mammalian protein expression projects. Prior to that, Kai worked as Senior Principal Scientist at ML Laboratories, where he was responsible for the development of targeted adenoviral vectors for cancer gene therapy approaches. At Vibalogics, Kai is central to the establishment of virus Process Development and Manufacturing capabilities, technical developments and the acquisition of many key clients.
Kai has a PhD in Transcriptional Regulation by Adenoviral E1A Proteins, and a Post-Doc, also on Transcriptional Regulation, from the University of Duisburg- Essen.